# Becton Dickinson & Co: Form 10-Q for the period ended Jun 30, 2010

- Company: [Becton Dickinson & Co](/companies/bdx.md) (CIK 10795)
- Form: 10-Q
- Filed: 2010-08-04
- Accepted by EDGAR: Aug 4, 2010, 14:27 ET
- Period: 2010-06-30
- Accession: 0000950123-10-072399
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/10795/000095012310072399/y82825e10vq.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/10795/000095012310072399/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2010-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2010-04-01 to 2010-06-30 | $1.88bn | us-gaap:SalesRevenueNet |
| Revenue | 9 months, 2009-10-01 to 2010-06-30 | $5.64bn | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2010-04-01 to 2010-06-30 | $905.8m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2009-10-01 to 2010-06-30 | $2.71bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months, 2010-04-01 to 2010-06-30 | $423.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2009-10-01 to 2010-06-30 | $1.30bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2010-04-01 to 2010-06-30 | $440.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2009-10-01 to 2010-06-30 | $1.32bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2010-04-01 to 2010-06-30 | $13.1m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2009-10-01 to 2010-06-30 | $39.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2010-04-01 to 2010-06-30 | $124.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2009-10-01 to 2010-06-30 | $377.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2010-04-01 to 2010-06-30 | $306.9m | us-gaap:ProfitLoss |
| Net income | 9 months, 2009-10-01 to 2010-06-30 | $920.9m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2010-04-01 to 2010-06-30 | $1.29 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2009-10-01 to 2010-06-30 | $3.82 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2010-04-01 to 2010-06-30 | $1.32 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2009-10-01 to 2010-06-30 | $3.91 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2010-04-01 to 2010-06-30 | 238,319,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2009-10-01 to 2010-06-30 | 241,151,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2009-10-01 to 2010-06-30 | $1.19bn | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 9 months, 2009-10-01 to 2010-06-30 | $330.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2009-10-01 to 2010-06-30 | $260.3m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months, 2009-10-01 to 2010-06-30 | $550.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2010-06-30 | $750.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2010-06-30 | $4.12bn | us-gaap:AssetsCurrent |
| Total assets | at 2010-06-30 | $9.03bn | us-gaap:Assets |
| Current liabilities | at 2010-06-30 | $1.53bn | us-gaap:LiabilitiesCurrent |
| Current portion of debt | at 2010-06-30 | $202.2m | us-gaap:DebtCurrent |
| Shareholders' equity | at 2010-06-30 | $5.15bn | us-gaap:StockholdersEquity |
| Shares outstanding | at 2010-06-30 | 232,145,867 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 36,998 characters.

#### Company Overview

Becton, Dickinson and Company (“BD”) is a global medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Our business consists of three worldwide business segments — BD Medical (“Medical”), BD Diagnostics (“Diagnostics”) and BD Biosciences (“Biosciences”). Our products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives.

#### Overview of Financial Results

BD reported third quarter revenues of $1.878 billion, representing an increase of 3% from the same period a year ago, and reflecting volume increases of approximately 4%, unfavorable foreign currency translation of 1% and price decreases of less than 1%. Solid revenue growth in the Medical segment and continued improvement in Biosciences sales offset slower growth in Diagnostics segment revenues. Sales in the United States of safety-engineered devices in the third quarter of 2010 were $277 million, representing a 2% increase from the prior year’s period. International sales of safety-engineered devices of $159 million in the third quarter of 2010 grew 7% above such sales in the prior year’s period, and were not materially impacted by foreign currency translation. Overall, third quarter international revenues were $1.049 billion, representing an increase of 3% above the prior year’s period, after taking into account an estimated 1% unfavorable impact due to foreign currency translation, inclusive of hedge losses.

The recently-enacted U.S. healthcare reform legislation contains certain tax provisions that will affect BD. The most significant impact is the medical device excise tax which imposes a 2.3% tax on certain U.S. sales of medical devices, beginning in January 2013. Sales of BD products which we estimate to be subject to this tax represented approximately 80% of BD’s total U.S. revenues in fiscal year 2009. In addition, the new legislation included a tax provision that eliminated the employer deduction of the Medicare Part D retiree drug subsidy, and, as a result, we recorded a charge of $8.9 million, or $0.04 per share, in the second quarter of fiscal year 2010.

As further discussed in our 2009 Annual Report on Form 10-K, we face currency exposure each reporting period that arises from translating the results of our worldwide operations to the U.S. dollar at exchange rates that fluctuate from the beginning of such period. From time to time, we purchase forward contracts to partially protect against adverse foreign exchange rate movements. Gains or losses on our derivative instruments are largely offset by the gains or losses on the underlying hedged transactions. We do not enter into derivative instruments for trading or speculative purposes. During the first quarter of 2010, the U.S. dollar weakened against most foreign currencies, primarily the Euro, compared with rates during the first quarter of 2009. While on a year-to-date basis, the U.S. dollar has strengthened against foreign currencies, particularly the Euro, our year-to-date revenues have been slightly favorably impacted by foreign currency translation. The favorable impact was partially offset by hedge losses, recorded in *Revenues,* resulting from our hedging activities. For further discussion refer to Note 12 in the Notes to Condensed Consolidated Financial Statements.

Comparisons of income from continuing operations between 2010 and 2009 are affected by the following items that are reflected in our 2010 and 2009 results:

- During the second quarter of fiscal year 2010, we recorded a non-cash charge of $8.9 million, or $0.04 diluted earnings per share from continuing operations, related to healthcare reform impacting Medicare Part D reimbursements.
- During the third quarter of fiscal year 2009, we recorded a tax benefit of $20 million, or $0.08 diluted earnings per share from continuing operations, relating to various tax settlements in multiple jurisdictions.
- During the second quarter of fiscal year 2009, we recorded a charge of $45 million, or $0.11 diluted earnings per share from continuing operations, associated with the pending settlement with the direct purchaser plaintiffs (which includes BD’s distributors) in certain antitrust class actions.

#### Results of Operations

#### Revenues

Refer to Note 6 in the Notes to Condensed Consolidated Financial Statements for segment financial data.

#### Medical Segment

The following is a summary of third quarter revenues by organizational unit:

| (millions of dollars) | Three months ended June 30, 2010 | 2009 | Total Change | Estimated Foreign Exchange Impact |
| --- | ---: | ---: | ---: | ---: |
| Medical Surgical Systems | $520 | $499 | 4.2% | 1.4% |
| Diabetes Care | 197 | 186 | 6.1% | (0.1%) |
| Pharmaceutical Systems | 255 | 264 | (3.5%) | (3.1%) |
| Ophthalmic Systems | 21 | 20 | 4.9% | (3.2%) |
| Total Revenues | $993 | $969 | 2.5% | (0.2%) |

Third quarter revenues of $993 million represented an increase of $24 million, or 2.5%, compared with the prior year’s quarter, including an estimated $2 million, or less than 1%, unfavorable impact due to foreign currency translation, inclusive of hedge losses. Growth in this segment was primarily driven by strong sales of Diabetes Care products including pen needles, offset in part by lower Pharmaceutical Systems revenues due to timing of orders in the quarter. Revenue growth also reflected an unfavorable comparison versus the prior-year period in which sales increased as a result of the H1N1 flu pandemic. Global sales of safety-engineered products were $203 million, as compared with $199 million in the prior year’s quarter, and included an estimated $0.5 million favorable impact due to foreign currency translation, net of hedge losses.

For the nine-month period ended June 30, 2010, global sales of safety-engineered products were $632 million, as compared with $575 million in the prior year’s period, and included an estimated $7 million favorable impact due to foreign currency translation, net of hedge losses. Total Medical Segment revenues for the nine-month period ended June 30, 2010 increased by 9% from the prior-year nine-month period, including an estimated 2% favorable impact from foreign currency translation, net of hedge losses.

#### Diagnostics Segment

The following is a summary of third quarter revenues by organizational unit:

| (millions of dollars) | Three months ended June 30, 2010 | 2009 | Total Change | Estimated Foreign Exchange Impact |
| --- | ---: | ---: | ---: | ---: |
| Preanalytical Systems | $304 | $292 | 3.9% | — |
| Diagnostic Systems | 273 | 274 | (0.5%) | (0.5%) |
| Total Revenues \* | $576 | $566 | 1.7% | (0.3%) |

\* Amounts may not add due to rounding

Third quarter revenues of $576 million represented an increase of $10 million, or 2%, over the prior year’s quarter, including an estimated $2 million, or less than 1%, unfavorable impact due to foreign currency translation, inclusive of hedge losses. Growth was primarily driven by Preanalytical Systems revenues in emerging markets, partially offset by lower lab testing volumes in the U.S. Diagnostics Systems revenues were unchanged from the prior-year period in which sales increased as a result of the H1N1 flu pandemic. Diagnostics Systems also experienced soft demand in the third quarter in the U.S and Western Europe due to lower diagnostic testing. Partially offsetting these testing declines was strong growth in the GeneOhm platform. Global sales of safety-engineered products in the Preanalytical Systems unit in the third quarter totaled $233 million, compared with $223 million in the prior year’s quarter, and included an estimated $0.4 million unfavorable impact due to foreign currency translation, inclusive of hedge losses. For the nine-month period ended June 30, 2010, global sales of safety-engineered products in the Preanalytical Systems unit were $677 million as compared with $642 million in the prior year’s period, and included an estimated $5 million favorable impact due to foreign currency translation, net of hedge losses. Total Diagnostics Segment revenues for the nine-month period ended June 30, 2010 increased by 5% from the prior-year nine-month period, including an estimated 1% favorable impact from foreign currency translation, net of hedge losses.

#### Biosciences Segment

The following is a summary of third quarter revenues by organizational unit:

| (millions of dollars) | Three months ended June 30, 2010 | 2009 | Total Change | Estimated Foreign Exchange Impact |
| --- | ---: | ---: | ---: | ---: |
| Cell Analysis | $230 | $210 | 9.9% | (3.7%) |
| Discovery Labware | 79 | 75 | 4.3% | (2.0%) |
| Total Revenues | $309 | $285 | 8.4% | (3.2%) |

Third quarter revenues of $309 million represented an increase of $24 million, or 8%, over the prior year’s quarter, including an estimated $9 million, or 3%, unfavorable impact due to foreign currency translation, inclusive of hedge losses. Revenue growth was primarily driven by Cell Analysis instrument and reagent sales in the U.S. and supplemental governmental funding in Japan. Revenue growth also benefitted from a favorable comparison to the prior-year period, which reflected weak demand for instruments in certain markets in fiscal year 2009. For the nine-month period ended June 30, 2010, total Biosciences Segment revenues increased by 5% from the prior-year period, including an estimated 3% unfavorable impact from foreign currency translation, which includes hedge losses. Biosciences revenues reflected a larger portion of our hedge losses than the Medical and Diagnostics segments, as these losses are allocated to the segments based on their proportionate share of international sales of U.S.-produced products. Because Biosciences products are substantially U.S.-produced, foreign currency translation had a relatively larger unfavorable impact on Biosciences revenues compared with the other segments for the quarter.

#### Segment Operating Income

#### Medical Segment

Segment operating income for the third quarter was $290 million, or 29.2% of Medical revenues, compared with $304 million, or 31.3% of segment revenues, in the prior year’s quarter. Gross profit margin was lower in the current quarter than the third quarter of 2009 due to unfavorable foreign currency translation, including hedge losses, as well as increases in certain raw material costs, higher manufacturing start-up costs and higher pension costs allocated to the segment. These unfavorable impacts on gross profit margin were partially offset by higher sales of products with higher gross margins and continued strength in manufacturing productivity. See further discussion on gross profit margin below. Selling and administrative expense as a percent of Medical revenues in the third quarter of 2010 was higher than the comparable amount in the third quarter of 2009, as continued spending controls were more than offset by unfavorable foreign currency translation. Research and development expenses for the quarter increased $4 million, or 12.4%, above the prior year’s period, reflecting increased investment in new products and platforms. Segment operating income for the nine-month period was $890 million, or 29.9% of Medical revenues, compared with $811 million, or 29.8% in the prior year’s period.

#### Diagnostics Segment

Segment operating income for the third quarter was $147 million, or 25.5% of Diagnostics revenues, compared with $155 million, or 27.3% of segment revenues, in the prior year’s quarter. Gross profit margin was lower in the current quarter than in the prior year’s quarter primarily due to unfavorable foreign currency translation, including hedge losses. Increases in certain raw material costs and higher pension costs allocated to the segment also contributed to the decrease from the prior period. These unfavorable impacts on gross profit margin were partially offset by productivity improvements. See further discussion on gross profit margin below. Selling and administrative expense as a percentage of Diagnostics revenues in the third quarter of 2010 was slightly lower than the comparable amount in the third quarter of 2009, as continued spending controls more than offset unfavorable foreign currency translation. Research and development expenses in the third quarter of 2010 increased $2 million, or 6.8% compared with the prior year’s period. Segment operating income for the nine-month period was $453 million, or 26.2% of Diagnostics revenues, compared with $451 million, or 27.4% in the prior year’s period.

#### Biosciences Segment

Segment operating income for the third quarter was $87 million, or 28.2% of Biosciences revenues, compared with $76 million, or 26.7% of segment revenues, in the prior year’s quarter. Gross profit margin was higher in the current quarter than the third quarter of 2009 reflecting higher sales of products with higher gross margins and a favorable comparison due to the unfavorable impact of plant restructuring costs and an asset impairment charge in the prior year’s period. These favorable variances from the prior year’s period were partially offset by the unfavorable impact of foreign currency translation, including hedge losses. See further discussion on gross profit margin below. Selling and administrative expense as a percent of Biosciences revenues for the quarter was lower compared with the prior year’s quarter, as continued spending controls more than offset unfavorable foreign currency translation. Research and development spending in the quarter increased $2 million, or 10.4% above the prior-year period. Segment operating income for the nine-month period was $270 million, or 28.9% of Biosciences revenues, compared with $268 million, or 30.1% in the prior year’s period.

#### Geographic Revenues

Revenues in the United States for the third quarter of $830 million represented an increase of $24 million, or 3%, over the prior year’s quarter. Growth in U.S. Medical segment revenues was primarily attributable to pen needle sales, which was partially offset by the H1N1 flu pandemic-related sales in the prior year’s period and the continued soft demand for Medical Surgical products, as discussed earlier. U.S. Diagnostics segment revenue growth was unfavorably impacted by reduced diagnostic testing and physician visits. Biosciences segment revenues in the U.S. reflected strong growth of instrument and reagent sales in the Cell Analysis unit. International revenues for the third quarter of $1.049 billion represented an increase of $34 million, or 3%, over the prior year’s quarter, including an estimated $13 million, or 1%, unfavorable impact due to foreign currency translation, inclusive of hedge losses. Medical and Diagnostic segment international revenues reflected strong growth in emerging markets, which was offset by slower growth in Europe. Biosciences segment international revenue growth on a foreign currency-neutral basis was driven by strong sales in Japan.

#### Gross Profit Margin

Gross profit margin was 51.8% for the third quarter, compared with 52.8% for the comparable prior-year period. Gross profit margin in the third quarter of 2010 as compared with the prior year’s period reflected an estimated unfavorable impact of 120 basis points from both foreign currency translation and the hedging of certain foreign currencies, in particular the Euro, as previously discussed above under “Overview of Financial Results.” The operating performance impact on gross margin was favorable by 20 basis points as compared with prior year. This resulted from higher sales of products with higher gross margins and increased productivity, which was partially offset by increases in certain raw material costs, higher manufacturing start-up costs and higher pension costs. Gross profit margin in the nine-month period of 2010 of 51.9% compared with the prior year’s period of 52.8% reflected an estimated unfavorable impact of foreign currency translation of 140 basis points resulting from both foreign currency translation and the hedging of certain foreign currencies, as previously discussed. Partially offsetting these losses was a net favorable operating performance impact of 50 basis points. Operating performance reflected higher sales of products with higher gross margins and decreases in certain raw material costs, partially offset by higher manufacturing start-up costs and higher pension costs.

#### Selling and Administrative Expense

Selling and administrative expense was 22.6% of revenues for the third quarter and 23.1% for the nine-month period, compared with 23.6% and 24.2%, respectively, for the prior year’s periods. Aggregate expenses for the third quarter reflected an unfavorable foreign exchange impact of $7 million and increased pension costs of $4 million. These increases were offset by a decrease in core spending of $6 million compared with the prior year’s period and an $11 million decrease in the deferred compensation liability, as further discussed below. Aggregate expenses for the nine-month period of 2010 reflected $38 million of unfavorable foreign exchange impacts, increased spending of $14 million related to our enterprise-wide program to update our business information systems, increased pension costs of $11 million, a $6 million increase in the deferred compensation plan liability and increases in core spending of $5 million. Aggregate expenses for the prior year’s nine-month period reflected the $45 million litigation charge previously discussed.

#### Research and Development Expense

Research and development expense was $109 million, or 5.8% of revenues, for the third quarter, an increase of 10% compared with the prior year’s amount of $98 million, or 5.4% of revenues, reflecting increased spending for key programs in each of our segments. Research and development expense was $310 million, or 5.5% of revenues, for the nine-month period in the current year, an increase of 5% compared with the prior year’s amount of $294 million, or 5.6% of revenues.

#### Non-Operating Expense and Income

Interest income was $2 million in the third quarter compared with $13 million in the prior year’s period. The decrease in the current year’s quarter compared with the prior year amount reflects investment losses on assets related to our deferred compensation plan. The related decrease in the deferred compensation plan liability was recorded as a decrease in selling and administrative expenses. The current quarter’s decrease also reflects the impact of lower interest rates compared with the prior year’s period, offset by the impact of higher investment levels. Interest income was $21 million in the nine-month period, compared with $19 million in the prior year’s period. The increase in the nine-month period ending June 30, 2010 compared with the prior year’s period resulted from year-to-date investment gains on assets related to our deferred compensation plan and higher investment levels, which was partially offset by the impact of lower interest rates during the period. The related year-to-date increase in the deferred compensation plan liability has resulted in a year-to-date increase in selling and administrative expenses. Interest expense was $13 million in the third quarter and $39 million in the nine-month period, compared with $11 million and $27 million, respectively, in the prior year’s periods. These increases reflect higher levels of long-term fixed rate debt, partially offset by lower interest rates on floating rate debt and a benefit from higher levels of capitalized interest.

#### Income Taxes

The income tax rate was 28.8% for the third quarter, compared with the prior year’s rate of 21.0%. The nine-month tax rate was 29.1% compared with the prior year’s rate of 24.5%. The increases in the income tax rates for the three-month and nine-month periods ending June 30, 2010 compared with the prior year’s periods reflect the benefit in the prior periods due to various tax settlements in multiple jurisdictions as discussed earlier in “Overview of Financial Results.” The increase for the nine-month period also reflects the impacts of a non-cash charge related to healthcare reform impacting Medicare Part D reimbursements as discussed earlier in “Overview of Financial Results” and the reinstated research and experimentation tax credit in the prior year’s first quarter.

#### Income from Continuing Operations and Diluted Earnings Per Share from Continuing Operations

Income from continuing operations and diluted earnings per share from continuing operations for the third quarter of 2010 were $306 million and $1.29, respectively. Income from continuing operations and diluted earnings per share from continuing operations for the prior year’s third quarter were $339 million and $1.38, respectively. The current quarter’s earnings reflect an estimated $0.10 overall net unfavorable impact of foreign exchange fluctuations. The prior period earnings included a $0.08 tax benefit relating to various tax settlements in multiple jurisdictions as discussed earlier in “Overview of Financial Results.” For the nine-month periods, income from continuing operations and diluted earnings per share from continuing operations were $920 million and $3.81, respectively, in 2010 and $907 million and $3.67, respectively, in 2009. The current period’s earnings reflected the $0.04 non-cash charge related to healthcare reform as well as an estimated $0.27 overall net unfavorable impact of foreign exchange fluctuations, including foreign exchange hedge losses, as discussed above. The prior-year period’s earnings included the $0.08 tax benefit relating to various tax settlements in multiple jurisdictions and the $0.11 litigation charge, as discussed earlier.

#### Liquidity and Capital Resources

Cash generated from operations, along with available cash and cash equivalents, is expected to be sufficient to fund our normal operating needs, including capital expenditures, cash dividends and common stock repurchases in 2010. Net cash provided by continuing operating activities was $1.194 billion during the first nine months of 2010, compared with $1.048 billion in the same period in 2009. The current period change in operating assets and liabilities was a net use of cash and reflected higher inventory levels.

Net cash used for continuing investing activities for the first nine months of the current year was $879 million, compared with $714 million in the prior-year period. Capital expenditures were $330 million in the first nine months of 2010 and $354 million in the same period in 2009. The current year amount also reflects the payment of $275 million of net cash relating to the HandyLab acquisition, which is discussed further in Note 9 in the Notes to Condensed Consolidated Financial Statements. In May 2010, the Company signed agreements to sell the

Ophthalmic Systems unit as well as the surgical blades, critical care and extended dwell catheter product platforms of the Medical Surgical Systems unit for $270 million. On July 30, 2010, the Company completed the sale of the Ophthalmic Systems unit and the surgical blades product platform. The Company expects to complete the sale of the critical care and extended dwell catheter product platforms during the fourth fiscal quarter 2010.

Net cash used for continuing financing activities for the first nine months of the current year was $956 million, compared with net cash provided by continuing financing activities of $162 million in the prior-year period. The change in short-term debt reflected the repayment of $200 million of 7.15% Notes, due October 1, 2009. For the first nine months of the current year, the Company repurchased $550 million of its common stock, compared with approximately $371 million of its common stock in the prior-year period. Aggregate common stock repurchases are estimated to be approximately $700 million for the full fiscal year 2010. At June 30, 2010, authorization to repurchase an additional 10.4 million common shares remained.

As of June 30, 2010, total debt of $1.7 billion represented 24.4% of total capital (shareholders’ equity, net non-current deferred income tax liabilities, and debt), versus 26.8% at September 30, 2009. Short-term debt decreased to 12% of total debt at the end of June 30, 2010, from 21% at September 30, 2009.

We have in place a commercial paper borrowing program that is available to meet our short-term financing needs, including working capital requirements. Borrowings outstanding under this program were $200 million at June 30, 2010. We have available a $1 billion syndicated credit facility with an expiration date in December 2012. This credit facility, under which there were no borrowings outstanding at June 30, 2010, provides backup support for our commercial paper program and can also be used for other general corporate purposes. This credit facility includes a single financial covenant that requires BD to maintain an interest expense coverage ratio (ratio of earnings before income taxes, depreciation and amortization to interest expense) of not less than 5-to-1 for the most recent four consecutive fiscal quarters. On the last eight measurement dates, this ratio has ranged from 26-to-1 to 34-to-1. In addition, we have informal lines of credit outside the United States.

#### Government Receivables

Accounts receivable balances include sales to government-owned or government-supported healthcare facilities. Because these customers are government owned or supported, we could be impacted by declines in sovereign credit ratings or by defaults in these countries. We continually evaluate all government receivables, particularly in Greece, Spain, Italy, and other parts of Western Europe, for potential collection risks associated with the availability of government funding and reimbursement practices.

In particular, we have experienced significant payment delays in Greece due to the government’s current liquidity issues which affect its ability to process payments to suppliers within Greece’s national healthcare system. The outstanding balances, net of reserves related to such sales, were approximately $34 million and $45 million at June 30, 2010 and September 30, 2009, respectively. If significant changes occur in the availability of government funding in Greece, we may not be able to fully collect on amounts due from these customers. We do not expect this concentration of credit risk to have a material adverse impact on our financial position or liquidity.

#### Cautionary Statement Regarding Forward-Looking Statements

BD and its representatives may from time-to-time make certain forward-looking statements in publicly released materials, both written and oral, including statements contained in filings with the Securities and Exchange Commission, press releases and our reports to shareholders. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance, as well as our strategy for growth, product development, regulatory approvals, market position and expenditures. All statements that address operating performance or events or developments that we expect or anticipate will occur in the future — including statements relating to volume growth, sales and earnings per share growth, cash flows or uses, and statements expressing views about future operating results — are forward-looking statements.

Forward-looking statements are based on current expectations of future events. The forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance, and speak only as of their dates. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements. Furthermore, we undertake no obligation to update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events and developments or otherwise, except as required by applicable law or regulations.

The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements. For further discussion of certain of these factors, see Item IA. Risk factors in our 2009 Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q.

- The current conditions in the global economy and financial markets, and the potential adverse effect on liquidity and access to capital resources for BD and/or its customers and suppliers, the cost of operating our business, the demand for our products and services (particularly in countries where governments are the primary payers of healthcare expenses and research), or our ability to produce our products, including the impact on developing countries. Also, the increase in sovereign debt during the financial crisis as a result of governmental intervention in the world economy poses additional risks to the global financial system and economic recovery.
- The consequences of the recently-enacted healthcare reform in the United States, which could result in reduced demand for our products, increased pricing pressures or otherwise adversely affect BD’s business.
- Changes in domestic and foreign healthcare industry practices that result in a reduction in procedures using our products or increased pricing pressures, including the continued consolidation among healthcare providers and trends toward managed care and healthcare cost containment.

36

- Regional, national and foreign economic factors, including inflation, deflation, and fluctuations in interest rates and, in particular, foreign currency exchange rates, and the potential effect on our revenues, expenses, margins and credit ratings.
- New or changing laws and regulations affecting our domestic and foreign operations, or changes in enforcement practices, including laws relating to trade, monetary and fiscal policies, taxation (including tax reforms that could adversely impact multinational corporations), sales practices, price controls, licensing and regulatory requirements for new products and products in the postmarketing phase. In particular, the U.S. and other countries may impose new requirements regarding registration, labeling or prohibited materials that may require us to re-register products already on the market or otherwise impact our ability to market our products. Environmental laws, particularly with respect to the emission of greenhouse gases, are also becoming more stringent throughout the world, which may increase our costs of operations or necessitate changes in our manufacturing plants or processes or those of our suppliers, or result in liability to BD.
- Product efficacy or safety concerns regarding our products resulting in product recalls, regulatory action on the part of the U.S. Food and Drug Administration (FDA) or foreign counterparts), declining sales and product liability claims, particularly in light of the current regulatory environment, including increased enforcement activity by the FDA.
- Competitive factors that could adversely affect our operations, including, new product introductions (for example, new forms of drug delivery) by our current or future competitors, increased pricing pressure due to the impact of low cost manufacturers as certain competitors have established manufacturing sites or have contracted with suppliers in low-cost manufacturing locations as a means to lower their costs, patents attained by competitors, particularly as patents on our products expire, and new entrants into our markets.
- The effects of natural disasters, including pandemic diseases, earthquakes, fire, wind or other destructive events, or the effects of climate change, on our ability to manufacture our products, (particularly where production of a product line is concentrated in one or more plants,) or our ability to source materials or components from suppliers that are needed for such manufacturing.
- Fluctuations in the cost and availability of oil-based resins and other raw materials, as well as certain sub-assemblies and finished goods, the ability to maintain favorable supplier arrangements and relationships (particularly with respect to sole-source suppliers) and the potential adverse effects of any disruption in the availability of such items.
- Difficulties inherent in product development, including the potential inability to successfully continue technological innovation, complete clinical trials, obtain regulatory approvals in the United States and abroad, obtain coverage and adequate

37

|  |  |
| --- | --- |
|  | reimbursement for new products, or gain and maintain market approval of products, as well as the possibility of infringement claims by competitors with respect to patents or other intellectual property rights, all of which can preclude or delay commercialization of a product. |
| **•** | Fluctuations in the demand for products we sell to pharmaceutical companies that are used to manufacture, or are sold with, the products of such companies, as a result of funding constraints, consolidation or otherwise. |
| **•** | Fluctuations in U.S. and international governmental funding and policies for life sciences research. |
| **•** | Our ability to achieve our projected level or mix of product sales. Our earnings forecasts are generated based on projected volumes and sales of many product types, some of which are more profitable than others. |
| **•** | Our ability to implement our ongoing upgrade of our enterprise resource planning system, as any delays or deficiencies in the design and implementation of our upgrade could adversely affect our business. |
| **•** | Pending and potential future litigation or other proceedings adverse to BD, including antitrust claims, product liability claims, patent infringement claims, and the availability or collectibility of insurance relating to any such claims. |
| **•** | The effect of adverse media exposure or other publicity regarding BD’s business or operations, including the effect on BD’s reputation or demand for its products. |
| **•** | The effects, if any, of governmental and media activities regarding the business practices of group purchasing organizations, which negotiate product prices on behalf of their member hospitals with BD and other suppliers. |
| **•** | The effect of market fluctuations on the value of assets in BD’s pension plans and to actuarial interest rate and asset return assumptions, which could require BD to make additional contributions to the plans or increase our pension plan expense. |
| **•** | Political conditions in international markets, including civil unrest, terrorist activity, governmental changes, restrictions on the ability to transfer capital across borders and expropriation of assets by a government. |
| **•** | Our ability to penetrate developing and emerging markets, which also depends on economic and political conditions, and how well we are able to acquire or form strategic business alliances with local companies and make necessary infrastructure enhancements to production facilities, distribution networks, sales equipment and technology. |

38

- The effects, if any, of future healthcare reform in the countries in which we do business, including changes in government pricing and reimbursement policies or other cost containment reforms.
- The impact of business combinations, including any volatility in earnings relating to acquired in-process research and development assets, and our ability to successfully integrate any business we may acquire.
- Our ability to obtain the anticipated benefits of restructuring programs, if any, that we may undertake.
- Issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission.

The foregoing list sets forth many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider this list to be a complete statement of all potential risks and uncertainties. BD does not intend to update any forward-looking statements, except as required by applicable laws or regulations.

## Controls and procedures

As filed, 797 characters.

An evaluation was carried out by BD’s management, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of BD’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as of June 30, 2010. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the design and operation of these disclosure controls and procedures were, as of the end of the period covered by this report, effective. There were no changes in our internal control over financial reporting during the fiscal quarter ended June 30, 2010 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 242 characters.

There have been no material changes from the risk factors disclosed in Part I, Item 1A, of our Annual Report on Form 10-K for the 2009 fiscal year, and Part II, Item 1A of our Quarterly Report on From 10-Q for the period ended March 31, 2010.

Filed Aug 4, 2010.
Source: SEC EDGAR, the filing index for accession 0000950123-10-072399. Last ingested by Listed: Nov 11, 2026, 03:43 ET. No prices; not investment advice.
